Let me verify the ownership status and size details.
Flamel Ireland Limited
Company overview. Flamel Ireland Limited (d/b/a Avadel Ireland) is an Irish-registered entity headquartered in Dublin. It is the Irish intellectual-property holding company within the Avadel group; SEC filings list it as a wholly-owned subsidiary of Avadel Pharmaceuticals plc (Nasdaq: AVDL). In 2014 Avadel's predecessor, Flamel Technologies, transferred substantially all group IP to Flamel Ireland. On February 12, 2026, Alkermes plc (Nasdaq: ALKS) completed its acquisition of Avadel, making Flamel Ireland an affiliate of Alkermes. The parent group reported roughly 188 employees and 2024 net product revenue of about $169 million; Flamel Ireland itself is an IP/asset-holding entity with no separately disclosed headcount or revenue.
Products / operations. Flamel Ireland does not itself manufacture or sell; it is the patent owner/licensor for the group's commercial product. It holds patents covering LUMRYZ (sodium oxybate) extended-release oral suspension, the first once-at-bedtime treatment for cataplexy or excessive daytime sleepiness in narcolepsy, approved by the FDA in May 2023. Patents at issue include modified-release gamma-hydroxybutyrate formulation and dosing claims (e.g., U.S. 11,602,512; 11,826,335). Avadel CNS Pharmaceuticals, LLC is the exclusive licensee of these patents.
Patent-litigation posture. Not an NPE. Flamel Ireland is a two-way litigant appearing on both sides of a branded-pharma competitor dispute with Jazz Pharmaceuticals, consistent with the case data (one plaintiff case, one defendant case): it was a defendant in Jazz Pharmaceuticals, Inc. et al. v. Avadel CNS Pharmaceuticals, LLC et al. (D. Del., filed 2021-05-12) and a plaintiff in Avadel CNS Pharmaceuticals, LLC et al. v. Jazz Pharmaceuticals, Inc. et al. (D. Del., filed 2022-04-14). Both are in the District of Delaware, a common venue for ANDA/Hatch-Waxman and IP disputes, not a plaintiff-friendly NPE venue.
Context. The litigation centers on the competing oxybate products LUMRYZ and Jazz's XYWAV/XYREM. Later Avadel–Jazz actions asserting additional Flamel-owned oxybate patents (e.g., U.S. 12,226,388 and 12,226,389) were dismissed with prejudice under a joint settlement in 2025, per PACER-based reporting; the earlier tracked cases remain part of this multi-year enforcement campaign by the Avadel group.